Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advance breast cancer

Journal of Clinical Oncology

Volumn 15, Issue 7, 1997, Pages 2510-2517

  Conte, Pier Franco ^a   Baldini, Editta ^a   Gennari, Alessandra ^a   Michelotti, Andrea ^a   Salvadori, Barbara ^a   Tibaldi, Carmelo ^a   Danesi, Romano ^a   Innocenti, Federico ^a   Gentile, Alfonso ^a   Dell'Anna, Rita ^a   Biadi, Ombretta ^a   Mariani, Mario ^a   Del Tacca, Mario ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030793972     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.7.2510     Document Type: Article

References (30)

1. A'Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67:801-805, 1993
2. Venturini, M, Bruzzi P, Del Mastro L, et al: Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first line CEF regimen in patients with metastatic breast cancer. J Clin Oncol 14:764-773, 1996
3. Seidman AD: The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 1:247-256, 1996
4. Seidman AD, Reichman BS, Crown JPA, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995
5. Abrams JC, Vena DH, Boltz J, et al: Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial. J Clin Oncol 13:2056-2065, 1995
6. Eisenhauer EA, ten Bokkel Huinink W, Swenerton KB, et al: European Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High dose versus low dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
7. Gianni L, Munzone E, Capri G, et al: Paclitaxel in metastatic breast cancer: A trial of two doses by a 3 hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87: 1169-1175, 1995
8. Seidman AD, Tiersten A, Hudis C, et al: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy in metastatic breast cancer. J Clin Oncol 13:2575-2581, 1995
9. Nabholtz JM, Gelman K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
10. Sledge GW Jr, Robert M, Sparano JA, et al: Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 21:15-18, 1994 (suppl 8)
11. Fisherman JS, Cowan KH, Noone K, et al: Phase I-II study of 72 hour infusional paclitaxel and doxorubicin with granulocyte-stimulating factor in patients with metastatic breast cancer. J Clin Oncol 14:774-782, 1996
12. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3 hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995
13. Gehl J, Boesgaard M, Paaske T, et al: Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann Oncol 7:687-693, 1996
14. Bonadonna G, Gianni L, Santoro A, et al: Drugs ten years later: Epirubicin. Ann Oncol 4:359-369, 1993
15. Gennari A, Salvadori B, Tognoni A, et al: Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. Ann Oncol 7:978-979, 1996
16. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
17. Villani F, Misrachi D, Galimberti M: Cardiac arrhytmia and ischaemic events after combination chemotherapy for testicular cancer. Eur Heart J 15:1533-1536, 1994
18. Jamis-Dow CA, Klecker R, Sarosy G, et al: Steady-state plasma concentration and effects of Taxol at a 250 mg/sqm dose in combination with granulocyte colony-stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 33:48-52, 1993
19. Jakobsen P, Sorensen B, Bastholt L, et al: The pharmacokinetics of high dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil and tamoxifen in metastatic breast cancer patients. Cancer Chemother Pharmacol 35:45-52, 1994
20. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmocokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
21. Mross K, Maessen P, von der Vijgh WJF, et al: Pharmacokinetics of epidoxorubicin and doxorubicin in humans. J Clin Oncol 6:517-526, 1988
22. Focan C, Andrien JM, Closan MT, et al: Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 11:1253-63, 1993
23. Marschner N, Kreienberg R, Souchon R, et al: Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: Interim analysis of a prospective randomized trial. Semin Oncol 21:10-16, 1994 (suppl 1)
24. Bastholt L, Dalmark M, Gjedde SB, et al: Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14:1146-1155, 1996
25. Plosker GL, Faulds D: Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in cancer chemotherapy. Drugs 45:788-856, 1993
26. Berg SL, Cowan KH, Balis FM, et al: Pharmacokinetic of Taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 86:143-145, 1994
27. Holmes FA, Madden T, Newman RA, et al: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14:2713-2721, 1996
28. Olson RD, Mushlin PS: Doxorubicin cardiotoxicity: Analysis of prevailing hypothesis. FASEB J 4:3076-3086, 1990
29. Catimel G, Spielmann M, Dieras V, et al: Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: A preliminary report on safety. Semin Oncol 23:24-27, 1996 (suppl 1)
30. Luck HJ, Thomsenn C, duBois A, et al: Interim analysis of a phase II study of epirubicin and paclitaxel as first line therapy in patients with metastatic breast cancer. Semin Oncol 23:33-36, 1996 (suppl 1)